Does the media refer more to ABT or ARAY?

In the previous week, Abbott Laboratories had 76 more articles in the media than Accuray. MarketBeat recorded 78 mentions for Abbott Laboratories and 2 mentions for Accuray. Abbott Laboratories' average media sentiment score of 1.18 beat Accuray's score of 0.94 indicating that Abbott Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 57 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 7 Negative mention(s) 0 Very Negative mention(s) Positive Accuray 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARAY or ISRG?

In the previous week, Intuitive Surgical had 68 more articles in the media than Accuray. MarketBeat recorded 70 mentions for Intuitive Surgical and 2 mentions for Accuray. Intuitive Surgical's average media sentiment score of 1.24 beat Accuray's score of 0.94 indicating that Intuitive Surgical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accuray 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intuitive Surgical 54 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ARAY or SYK?

Stryker has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Accuray $428.57M 0.10 -$1.59M -$0.37 N/A Stryker $25.12B 4.72 $3.25B $8.64 35.76

Is ARAY or SYK more profitable?

Stryker has a net margin of 13.20% compared to Accuray's net margin of -10.76%. Stryker's return on equity of 23.42% beat Accuray's return on equity. Company Net Margins Return on Equity Return on Assets Accuray -10.76% -79.43% -10.38% Stryker 13.20% 23.42% 11.04%

Does the media favor ARAY or SYK?

In the previous week, Stryker had 30 more articles in the media than Accuray. MarketBeat recorded 32 mentions for Stryker and 2 mentions for Accuray. Stryker's average media sentiment score of 1.44 beat Accuray's score of 0.94 indicating that Stryker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accuray 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stryker 29 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, MDT or ARAY?

Medtronic has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medtronic $36.36B 2.83 $4.80B $3.73 21.52 Accuray $428.57M 0.10 -$1.59M -$0.37 N/A

Is MDT or ARAY more profitable?

Medtronic has a net margin of 13.20% compared to Accuray's net margin of -10.76%. Medtronic's return on equity of 14.61% beat Accuray's return on equity. Company Net Margins Return on Equity Return on Assets Medtronic 13.20% 14.61% 7.80% Accuray -10.76% -79.43% -10.38%

Does the media refer more to MDT or ARAY?

In the previous week, Medtronic had 55 more articles in the media than Accuray. MarketBeat recorded 57 mentions for Medtronic and 2 mentions for Accuray. Medtronic's average media sentiment score of 1.14 beat Accuray's score of 0.94 indicating that Medtronic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medtronic 46 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Accuray 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Accuray (ARAY) Competitors

$0.35 +0.01 (+3.72%)

As of 11:19 AM Eastern

Compare

ARAY vs. RMTI, ABT, ISRG, SYK, and MDT

Should you buy Accuray stock or one of its competitors? MarketBeat compares Accuray with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Accuray include Rockwell Medical (RMTI), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Stryker (SYK), and Medtronic (MDT). These companies are all part of the "health care equipment" industry.

How does Accuray compare to Rockwell Medical?

Accuray (NASDAQ:ARAY) and Rockwell Medical (NASDAQ:RMTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Accuray currently has a consensus price target of $2.00, indicating a potential upside of 464.97%. Rockwell Medical has a consensus price target of $2.00, indicating a potential upside of 211.04%. Given Accuray's higher probable upside, research analysts plainly believe Accuray is more favorable than Rockwell Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Rockwell Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

64.1% of Accuray shares are owned by institutional investors. Comparatively, 23.3% of Rockwell Medical shares are owned by institutional investors. 4.4% of Accuray shares are owned by insiders. Comparatively, 4.6% of Rockwell Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Accuray has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Rockwell Medical has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market.

Accuray has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$428.57M	0.10	-$1.59M	-$0.37	N/A
Rockwell Medical	$69.26M	0.37	-$5.31M	-$0.15	N/A

Rockwell Medical has a net margin of -7.98% compared to Accuray's net margin of -10.76%. Rockwell Medical's return on equity of -15.41% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accuray	-10.76%	-79.43%	-10.38%
Rockwell Medical	-7.98%	-15.41%	-9.62%

In the previous week, Accuray had 1 more articles in the media than Rockwell Medical. MarketBeat recorded 2 mentions for Accuray and 1 mentions for Rockwell Medical. Rockwell Medical's average media sentiment score of 1.87 beat Accuray's score of 0.94 indicating that Rockwell Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Accuray	Positive
Rockwell Medical	Very Positive

Summary

Rockwell Medical beats Accuray on 10 of the 16 factors compared between the two stocks.

How does Accuray compare to Abbott Laboratories?

Abbott Laboratories (NYSE:ABT) and Accuray (NASDAQ:ARAY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Abbott Laboratories has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Accuray has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by insiders. Comparatively, 4.4% of Accuray shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Abbott Laboratories has a net margin of 13.90% compared to Accuray's net margin of -10.76%. Abbott Laboratories' return on equity of 17.62% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	13.90%	17.62%	10.01%
Accuray	-10.76%	-79.43%	-10.38%

Abbott Laboratories presently has a consensus target price of $118.38, suggesting a potential upside of 34.15%. Accuray has a consensus target price of $2.00, suggesting a potential upside of 464.97%. Given Accuray's higher possible upside, analysts clearly believe Accuray is more favorable than Abbott Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Abbott Laboratories had 76 more articles in the media than Accuray. MarketBeat recorded 78 mentions for Abbott Laboratories and 2 mentions for Accuray. Abbott Laboratories' average media sentiment score of 1.18 beat Accuray's score of 0.94 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	57 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	7 Negative mention(s)	0 Very Negative mention(s)	Positive
Accuray	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abbott Laboratories has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$45.13B	3.41	$6.52B	$3.57	24.72
Accuray	$428.57M	0.10	-$1.59M	-$0.37	N/A

Summary

Abbott Laboratories beats Accuray on 14 of the 17 factors compared between the two stocks.

How does Accuray compare to Intuitive Surgical?

Accuray (NASDAQ:ARAY) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Accuray has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, Intuitive Surgical has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Intuitive Surgical has a net margin of 28.15% compared to Accuray's net margin of -10.76%. Intuitive Surgical's return on equity of 15.98% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accuray	-10.76%	-79.43%	-10.38%
Intuitive Surgical	28.15%	15.98%	14.07%

In the previous week, Intuitive Surgical had 68 more articles in the media than Accuray. MarketBeat recorded 70 mentions for Intuitive Surgical and 2 mentions for Accuray. Intuitive Surgical's average media sentiment score of 1.24 beat Accuray's score of 0.94 indicating that Intuitive Surgical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accuray	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intuitive Surgical	54 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Accuray currently has a consensus price target of $2.00, suggesting a potential upside of 464.97%. Intuitive Surgical has a consensus price target of $571.28, suggesting a potential upside of 37.25%. Given Accuray's higher probable upside, equities analysts plainly believe Accuray is more favorable than Intuitive Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Intuitive Surgical	1 Sell rating(s)	7 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.67

64.1% of Accuray shares are held by institutional investors. Comparatively, 83.6% of Intuitive Surgical shares are held by institutional investors. 4.4% of Accuray shares are held by insiders. Comparatively, 0.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Intuitive Surgical has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$428.57M	0.10	-$1.59M	-$0.37	N/A
Intuitive Surgical	$10.06B	14.65	$2.86B	$8.25	50.45

Summary

Intuitive Surgical beats Accuray on 14 of the 16 factors compared between the two stocks.

How does Accuray compare to Stryker?

Accuray (NASDAQ:ARAY) and Stryker (NYSE:SYK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Accuray presently has a consensus target price of $2.00, indicating a potential upside of 464.97%. Stryker has a consensus target price of $395.33, indicating a potential upside of 27.94%. Given Accuray's higher probable upside, equities research analysts plainly believe Accuray is more favorable than Stryker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Stryker	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.73

Accuray has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

In the previous week, Stryker had 30 more articles in the media than Accuray. MarketBeat recorded 32 mentions for Stryker and 2 mentions for Accuray. Stryker's average media sentiment score of 1.44 beat Accuray's score of 0.94 indicating that Stryker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accuray	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stryker	29 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stryker has a net margin of 13.20% compared to Accuray's net margin of -10.76%. Stryker's return on equity of 23.42% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accuray	-10.76%	-79.43%	-10.38%
Stryker	13.20%	23.42%	11.04%

Stryker has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$428.57M	0.10	-$1.59M	-$0.37	N/A
Stryker	$25.12B	4.72	$3.25B	$8.64	35.76

64.1% of Accuray shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 4.4% of Accuray shares are held by insiders. Comparatively, 4.6% of Stryker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Stryker beats Accuray on 14 of the 16 factors compared between the two stocks.

How does Accuray compare to Medtronic?

Medtronic (NYSE:MDT) and Accuray (NASDAQ:ARAY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Medtronic has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medtronic	$36.36B	2.83	$4.80B	$3.73	21.52
Accuray	$428.57M	0.10	-$1.59M	-$0.37	N/A

Medtronic presently has a consensus price target of $99.00, suggesting a potential upside of 23.31%. Accuray has a consensus price target of $2.00, suggesting a potential upside of 464.97%. Given Accuray's higher probable upside, analysts clearly believe Accuray is more favorable than Medtronic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medtronic	0 Sell rating(s)	11 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.61
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

82.1% of Medtronic shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 0.3% of Medtronic shares are held by company insiders. Comparatively, 4.4% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Medtronic had 55 more articles in the media than Accuray. MarketBeat recorded 57 mentions for Medtronic and 2 mentions for Accuray. Medtronic's average media sentiment score of 1.14 beat Accuray's score of 0.94 indicating that Medtronic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medtronic	46 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Accuray	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medtronic has a net margin of 13.20% compared to Accuray's net margin of -10.76%. Medtronic's return on equity of 14.61% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medtronic	13.20%	14.61%	7.80%
Accuray	-10.76%	-79.43%	-10.38%

Medtronic has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Accuray has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

Summary

Medtronic beats Accuray on 13 of the 16 factors compared between the two stocks.

Get Accuray News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARAY vs. The Competition

Export

Metric	Accuray	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$42.11M	$7.06B	$6.50B	$12.32B
Dividend Yield	N/A	1.21%	2.67%	5.66%
P/E Ratio	-0.96	48.29	24.00	24.65
Price / Sales	0.10	85.57	543.88	171.03
Price / Cash	7.66	25.59	27.48	37.92
Price / Book	0.49	6.90	10.73	6.84
Net Income	-$1.59M	$159.20M	$3.56B	$337.45M
7 Day Performance	-0.14%	-0.46%	1.34%	2.48%
1 Month Performance	31.11%	5.51%	2.25%	4.36%
1 Year Performance	-70.98%	2.40%	26.20%	32.45%

Accuray Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARAY Accuray	2.4973 of 5 stars	$0.35 +3.7%	$2.00 +465.0%	-72.0%	$42.11M	$428.57M	N/A	1,040
RMTI Rockwell Medical	3.6544 of 5 stars	$0.66 -0.5%	$2.00 +202.6%	-33.5%	$26.23M	$69.26M	N/A	300	Positive News Gap Up
ABT Abbott Laboratories	4.9846 of 5 stars	$90.46 -0.7%	$119.09 +31.6%	-35.1%	$158.63B	$45.13B	25.34	115,000	Positive News Dividend Announcement Analyst Forecast Analyst Revision
ISRG Intuitive Surgical	4.3015 of 5 stars	$418.58 -0.8%	$573.63 +37.0%	-19.7%	$149.48B	$10.06B	50.74	17,021	Positive News Analyst Forecast
SYK Stryker	4.9231 of 5 stars	$301.75 -1.3%	$395.33 +31.0%	-17.2%	$117.18B	$25.12B	34.92	56,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARAY) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Accuray (ARAY) Competitors

ARAY vs. RMTI, ABT, ISRG, SYK, and MDT

How does Accuray compare to Rockwell Medical?

Summary

How does Accuray compare to Abbott Laboratories?

Summary

How does Accuray compare to Intuitive Surgical?

Summary

How does Accuray compare to Stryker?

Summary

How does Accuray compare to Medtronic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARAY vs. The Competition

Accuray Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Accuray (ARAY) Competitors

ARAY vs. RMTI, ABT, ISRG, SYK, and MDT

How does Accuray compare to Rockwell Medical?

Do analysts recommend ARAY or RMTI?

Do institutionals and insiders have more ownership in ARAY or RMTI?

Which has more risk & volatility, ARAY or RMTI?

Which has stronger earnings & valuation, ARAY or RMTI?

Is ARAY or RMTI more profitable?

Does the media favor ARAY or RMTI?

Summary

How does Accuray compare to Abbott Laboratories?

Which has more risk and volatility, ABT or ARAY?

Do insiders and institutionals hold more shares of ABT or ARAY?

Is ABT or ARAY more profitable?

Do analysts rate ABT or ARAY?

Does the media refer more to ABT or ARAY?

Which has better earnings and valuation, ABT or ARAY?

Summary

How does Accuray compare to Intuitive Surgical?

Which has more volatility & risk, ARAY or ISRG?

Is ARAY or ISRG more profitable?

Does the media favor ARAY or ISRG?

Do analysts recommend ARAY or ISRG?

Do insiders and institutionals hold more shares of ARAY or ISRG?

Which has better valuation and earnings, ARAY or ISRG?

Summary

How does Accuray compare to Stryker?

Do analysts recommend ARAY or SYK?

Which has more volatility and risk, ARAY or SYK?

Does the media favor ARAY or SYK?

Is ARAY or SYK more profitable?

Which has preferable valuation and earnings, ARAY or SYK?

Do insiders & institutionals believe in ARAY or SYK?

Summary

How does Accuray compare to Medtronic?

Which has preferable earnings and valuation, MDT or ARAY?

Do analysts rate MDT or ARAY?

Do insiders & institutionals hold more shares of MDT or ARAY?

Does the media refer more to MDT or ARAY?

Is MDT or ARAY more profitable?

Which has more risk & volatility, MDT or ARAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARAY vs. The Competition

Accuray Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools